Zobrazeno 1 - 10
of 20
pro vyhledávání: '"Darren Weissman"'
Autor:
Javier Cid-Ruzafa, Brian E. Lacy, Anna Schultze, Mai Duong, Yi Lu, Mireia Raluy-Callado, Robert Donaldson, Darren Weissman, Ainhoa Gómez-Lumbreras, Dan Ouchi, Maria Giner-Soriano, Rosa Morros, Ahunna Ukah, Daniel Pohl
Publikováno v:
Therapeutic Advances in Gastroenterology, Vol 15 (2022)
Introduction: Linaclotide is approved for adults with moderate-to-severe irritable bowel syndrome (IBS) with constipation (IBS-C). Linaclotide is not indicated for weight loss or for patients with inflammatory bowel disease (IBD); it is contraindicat
Externí odkaz:
https://doaj.org/article/293ffc018ae94683aad4234c5301a1d6
Publikováno v:
Therapeutic Advances in Gastroenterology, Vol 14 (2021)
Background: Eluxadoline, a United States Food and Drug Administration (FDA)-approved treatment for irritable bowel syndrome with diarrhea (IBS-D), underwent a change to its US prescribing information on 21 April 2017, contraindicating it in patients
Externí odkaz:
https://doaj.org/article/b073d1d0c7f0469d9aa1ab43af5ba6a1
Autor:
Neel R. Gandhi, James C.M. Brust, Prashini Moodley, Darren Weissman, Moonseong Heo, Yuming Ning, Anthony P. Moll, Gerald H. Friedland, A. Willem Sturm, N. Sarita Shah
Publikováno v:
Emerging Infectious Diseases, Vol 20, Iss 3, Pp 394-401 (2014)
Multidrug- (MDR) and extensively drug-resistant tuberculosis (XDR TB) are commonly associated with Beijing strains. However, in KwaZulu-Natal, South Africa, which has among the highest incidence and mortality for MDR and XDR TB, data suggest that non
Externí odkaz:
https://doaj.org/article/15cc1ad23d924f56b69c27a314e2f498
Autor:
Jason R Andrews, N Sarita Shah, Darren Weissman, Anthony P Moll, Gerald Friedland, Neel R Gandhi
Publikováno v:
PLoS ONE, Vol 5, Iss 12, p e15735 (2010)
Multidrug-resistant (MDR) and extensively drug-resistant (XDR) tuberculosis (TB) have emerged in high-HIV-prevalence settings, which generally lack laboratory infrastructure for diagnosing TB drug resistance. Even where available, inherent delays wit
Externí odkaz:
https://doaj.org/article/6d940e982edc43b4a6ac4ed01c0ed30d
Autor:
Ramesh Boinpally, Darren Weissman
Publikováno v:
Clinical pharmacology in drug developmentReferences.
Eluxadoline is approved for the treatment of diarrhea-predominant irritable bowel syndrome in the United States. The impact of renal impairment on the pharmacokinetic (PK) parameters of eluxadoline is currently unknown. This phase 1, open-label, para
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b6220d0caf2c793660f5e6dd7d4902c2
https://pubmed.ncbi.nlm.nih.gov/36504331
https://pubmed.ncbi.nlm.nih.gov/36504331
Publikováno v:
Clinical pharmacology in drug development. 11(11)
Eluxadoline is a mixed μ-opioid, κ-opioid receptor agonist, and δ-opioid receptor antagonist, approved in the United States for adults with diarrhea-predominant irritable bowel syndrome. This phase 1, single-center, open-label, single-sequence stu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ab01d6ddd0dcf8015d72f6767eb304aa
https://pubmed.ncbi.nlm.nih.gov/35938453
https://pubmed.ncbi.nlm.nih.gov/35938453
Autor:
Elizabeth P. Shea, Jeffrey M. Johnston, Mark G. Currie, S J Shiff, Judy Nee, Wieslaw Bochenek, Anthony Lembo, Kenneth Tripp, Susan M. Fox, Courtney E. Walls, Darren Weissman
Background: Linaclotide is approved for treating irritable bowel syndrome with constipation (IBS-C; 290 µg QD) and chronic idiopathic constipation (CIC; 145 µg or 72 µg QD). These analyses aimed to assess linaclotide safety in a large, pooled Phas
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e29132626b1d9005915a2083c855be55
Autor:
Gerald Friedland, Neel R. Gandhi, Moonseong Heo, Prashini Moodley, James C.M. Brust, N. Sarita Shah, A. Willem Sturm, Anthony P. Moll, Yuming Ning, Darren Weissman
Publikováno v:
Emerging Infectious Diseases. 20:394-401
Multidrug- (MDR) and extensively drug-resistant tuberculosis (XDR TB) are commonly associated with Beijing strains. However, in KwaZulu-Natal, South Africa, which has among the highest incidence and mortality for MDR and XDR TB, data suggest that non
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7119549773cf778155b4e2a9934d9da2
https://doi.org/10.3201/eid2003.131083
https://doi.org/10.3201/eid2003.131083
Autor:
Elena Shashkina, A. Willem Sturm, Prashini Moodley, Barun Mathema, Barry N. Kreiswirth, Inga Elson, Melissa Ramathal, N. Sarita Shah, Richard Rothenberg, Neel R. Gandhi, Anthony P. Moll, Darren Weissman, Gerald Friedland
Publikováno v:
The Journal of Infectious Diseases. 207:9-17
Background. Extensively drug-resistant tuberculosis (XDR-tuberculosis) is a global public health threat, but few data exist elucidating factors driving this epidemic. The initial XDR-tuberculosis report from South Africa suggested transmission is an
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::369c048a13b6cf38f2efe3fca8983f4a
https://doi.org/10.1093/infdis/jis631
https://doi.org/10.1093/infdis/jis631
Autor:
Anthony Lembo, Kenneth Tripp, Susan M. Fox, Steven J. Shiff, Wieslaw Bochenek, Judy Nee, Jeffrey M. Johnston, Darren Weissman, Karel Van Loon, Elizabeth P. Shea
Publikováno v:
American Journal of Gastroenterology. 112:S251-S252
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c1c0b5c49bf82dc704714b9396baa11d
https://doi.org/10.14309/00000434-201710001-00477
https://doi.org/10.14309/00000434-201710001-00477